SLNO (SLNO)
Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Live quote temporarily unavailable — press releases and news are still shown below.
No company overview is available for SLNO yet.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
SOLNO Board Recommends Neurocrine Acquisition at $53 Per Share
# 📝 What This Document Is 📄 This document is an SEC filing called a Schedule 14D-9. Think of it as a comprehensive, legally required informational packet provided to stockholders when a major corporate event, like a merger or acquisition, is proposed. 🚨 Since a deal was being discussed, the Sole
Neurocrine buys Soleno for $53 per share in all-cash merger
# 📰 What This Document Is 📃 This document is a highly formal **Offer to Purchase** (an SEC filing, Form SC TO-T). Essentially, it is a formal, legally detailed proposal from one company to another. 👉 It means that Neurocrine Biosciences, Inc., is offering to buy out every single share of Soleno
SOLENO THERAPEUTICS INC — SC TO-C Filing
# 🧾 What This Document Is This is a transcript of a **corrected investor conference call** from April 6, 2026. Neurocrine Biosciences (NBIX) is explaining its plan to acquire Soleno Therapeutics (SLNO). This call followed the official announcement and is part of the SEC filing process for a tender
SOLENO THERAPEUTICS INC — SC TO-C Filing
# 🧾 What This Document Is This is a series of announcements filed with the SEC (form SC TO-C) about a **planned acquisition**. Neurocrine Biosciences (NBIX) is telling the world it plans to buy all of Soleno Therapeutics (SLNO) shares through a process called a **tender offer**. It's not the final
SEC filings
All filings →Insider trades
All insider trades →SLNO has no reported insider trades in the last 90 days.